Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma Název časopisu Journal of clinical oncology

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F10%3A%230000977" target="_blank" >RIV/65269705:_____/10:#0000977 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma Název časopisu Journal of clinical oncology
Original language description
High-dose chemotherapy (HDCT) followed by autologous stem-cell transplantation (PBSCT) has become the standard treatment for patients with relapsed Hodgkin's lymphoma (HL). The intensity of treatment needed is unclear. This European intergroup study evaluated the impact of sequential high-dose chemotherapy (SHDCT) before myeloablative therapy. PATIENTS: Patients with histologically confirmed, relapsed HL were treated with two cycles of DHAP. In the standard arm (A), patients received myeloablative therapy with BEAM followed by PBSCT. Patients in the experimental arm (B) also received sequential cyclophosphamide, methotrexate and etoposide in high-doses before BEAM. RESULTS: Mortality was similar in both arms (20% and 18%). With a median observation time of 42 months, there was no significant difference in terms of FFTF (P = .56) and OS (P = .82) between arms.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FD - Oncology and haematology
OECD FORD branch
—

Publication year
2010
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)